TD Waterhouse Canada Inc. cut its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 16.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 787,067 shares of the biopharmaceutical company's stock after selling 153,811 shares during the period. TD Waterhouse Canada Inc.'s holdings in Pfizer were worth $20,897,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Retirement Wealth Solutions LLC purchased a new stake in Pfizer during the fourth quarter worth $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer during the 4th quarter worth $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Pfizer during the 4th quarter worth $28,000. Noble Wealth Management PBC bought a new stake in Pfizer during the fourth quarter valued at about $31,000. Finally, Bernard Wealth Management Corp. bought a new position in Pfizer in the fourth quarter worth about $33,000. Institutional investors own 68.36% of the company's stock.
Pfizer Stock Performance
Shares of PFE stock traded down $0.15 during trading hours on Wednesday, hitting $22.38. The company's stock had a trading volume of 50,748,501 shares, compared to its average volume of 40,559,569. The stock has a market cap of $126.93 billion, a PE ratio of 15.87, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company has a 50 day moving average of $24.69 and a 200 day moving average of $26.06. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.
Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's revenue was up 24.7% on a year-over-year basis. During the same period in the prior year, the company earned $0.10 earnings per share. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
Pfizer Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.69%. Pfizer's payout ratio is presently 121.99%.
Insiders Place Their Bets
In other news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.06% of the company's stock.
Analyst Ratings Changes
A number of research firms have recently weighed in on PFE. Cantor Fitzgerald started coverage on shares of Pfizer in a research report on Tuesday. They issued a "neutral" rating and a $24.00 price objective on the stock. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $29.57.
Read Our Latest Analysis on PFE
About Pfizer
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
